Article

New Type of Small-Cell Lung Cancer Discovered

The discovery may pave the way for the development of personalized medicine in order to target this newly discovered form of the disease.

Researchers have recently discovered a new type of small-cell lung cancer (SCLC), and the discovery may pave the way for the development of personalized medicine in order to target this newly discovered form of the disease.

The discovery of this previously unnoticed form of the disease occurred as a result of a study of SCLC that applied domain-focused CRISPR screening, a gene-editing tool, to human cancer cell lines in order to identify the transcription factor, POU2F3, as a powerful dependency in a subset of SCLC.

“These data reveal POU2F3 as a cell identity determinant and a dependency in a tuft cell-like variant of SCLC, which may reflect a previously unrecognized cell of origin or a trans-differentiation event in this disease,” concluded the study.

Click to continue reading on The American Journal of Managed Care.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com